NCT01885676.

Trial name or title	Plasma Rich in Growth Factors (PRGF‐Endoret) in the Treatment of Androgenetic Alopecia
Methods	This is a double‐blind randomised placebo‐controlled trial
Participants	Inclusion criteria 24 men and women with androgenetic alopecia (18 to 65 years) (Ludwig scale I and II, and the Hamilton‐Norwood score II‐VI). Exclusion criteria No androgenetic alopecia. Telogen and anagen effluvium. Active inflammation or infection in the intervention area. Presence of active systemic infections. Background of cancerous or precancerous lesions. Background of connective or rheumatic diseases. Suffering from any serious blood disorders. To have undergone treatments for alopecia in the previous 6 months. Previous hair implants. Intake of drugs that affect hair loss. Be undergoing immunosuppressive therapy or anticoagulants, or both. Known intolerance to mesotherapy. Taking contraceptives containing cyproterone acetate. Pregnancy. In general, any limitations that would prevent the proper application of both treatments and the right monitoring of the efficacy variables.
Interventions	Plasma Rich in Growth Factors (PRGF‐Endoret). Saline solution.
Outcomes	Primary outcomes Change from baseline in hair density at three months (number of hairs per cm²). Secondary outcomes Hair width (µm). Anagen/telogen ratio. Terminal hair density. Vellus hair density.
Starting date	Not stated
Contact information	Eduardo Anitua, MD, DDS, PhD, eduardoanitua@eduardoanitua.com
Notes	We accessed the website on 3 August 2015, which was last updated on 24 December 2013. This is same as EUCTR2013‐002740‐85‐ES above. Both are known under 'BTI‐01D‐EC/12/ALO', but with another contact name virginia.cuadrado@bti‐implant.es